Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Oxaliplatin in Rectal Cancer
- Conditions
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 46
- Registration Number
- NCT00259363
- Locations
- 🇪🇸
Sanofi-Aventis, Barcelona, Spain
Oxaliplatin in Esophagus Cancer (Advanced) 1st Line
- Conditions
- Interventions
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 41
- Registration Number
- NCT00259402
- Locations
- 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain
Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults
- Conditions
- First Posted Date
- 2005-11-28
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 230
- Registration Number
- NCT00258947
Insulin Glargine During and After the Period of Fasting in Ramadan
- Conditions
- First Posted Date
- 2005-11-28
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 450
- Registration Number
- NCT00258804
Docetaxel in Non Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2005-11-28
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 140
- Registration Number
- NCT00258739
- Locations
- 🇪🇸
Sanofi-Aventis, Barcelona, Spain
RIAT Registry: Reason for Not Intensifying Antihypertensive Treatment
- Conditions
- First Posted Date
- 2005-11-28
- Last Posted Date
- 2007-11-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 31870
- Registration Number
- NCT00258921
Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients
- Conditions
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2009-04-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 281
- Registration Number
- NCT00257257
- Locations
- 🇵🇱
Sanofi-Aventis Administrative Office, Warszawa, Poland
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
- Conditions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 467
- Registration Number
- NCT00256113
- Locations
- 🇵🇹
Sanofi-Aventis Administrative Office, Porto Salvo, Portugal
Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent Asthma
- Conditions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2009-04-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1568
- Registration Number
- NCT00254956
- Locations
- 🇫🇷
Sanofi-Aventis, Chilly-Mazarin, France
Immunogenicity and Safety of Pentaxim in South African Infants
- Conditions
- Interventions
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2012-04-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 212
- Registration Number
- NCT00254969